Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Natera Signatera PMDA Approval Bladder Cancer

Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026

Sentiment
10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands Natera's addressable market in Japan for its Signatera molecular residual disease test, a positive long-term revenue driver though commercial launch is not expected until the first half of 2027. Near-term market reaction was muted to slightly negative, with Natera shares down 1.47 percent pre-market, suggesting the approval was largely anticipated by investors.

healthcare biotechnology diagnostics

Natera announced that its Signatera test received regulatory approval from Japan's Japan — Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports the use of Signatera to guide adjuvant atezolizumab treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first half of 2027, following the PMDA approval of atezolizumab in MIBC. The regulatory approval was supported by data from IMvigor011, a randomized, double-blind phase III clinical trial that evaluated Signatera-guided adjuvant atezolizumab in patients with MIBC, and included more than 20 participating sites in Japan. This marks Signatera's second PMDA authorization in Japan, after receiving approval in colorectal cancer in June 2026. It follows the United States — Food and Drug Administration approval of Signatera as a companion diagnostic for adjuvant atezolizumab in MIBC, as well as a recently published Category 1 recommendation for MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network Clinical Practice Guidelines for Bladder Cancer. Bladder cancer affects more than 34,000 people in Japan each year, with approximately 20-25 percent of newly diagnosed cases classified as muscle-invasive. Natera shares traded down 1.47 percent to $365.20 in pre-market trading on Nasdaq.

95 Japan — Pharmaceuticals and Medical Devices Agency approved Signatera companion diagnostic Natera
80 Natera announced regulatory approval
50 United States — Food and Drug Administration approved Signatera companion diagnostic Natera
40 National Comprehensive Cancer Network published Category 1 recommendation
stock
Natera is the central actor, receiving its second PMDA authorization for Signatera in Japan and planning a commercial launch in MIBC in the first half of 2027. The approval expands its oncology diagnostics footprint but near-term revenue contribution is limited, and shares fell 1.47 percent pre-market.
Importance 100.0 Sentiment 15.0
govactor
Japan's regulator granted the companion diagnostic approval for Signatera in muscle-invasive bladder cancer, enabling Natera's planned Japanese launch.
Importance 80.0 Sentiment 0.0
cnt
Japan is the market where the approval applies, with more than 34,000 bladder cancer cases annually and 20-25 percent muscle-invasive, representing the commercial opportunity for Natera.
Importance 45.0 Sentiment 0.0
subs
F. Hoffmann-La Roche — Genentech's atezolizumab (Tecentriq) is the therapy that Signatera guides, so the approval supports companion diagnostic use alongside its drug in Japan.
Importance 40.0 Sentiment 5.0
govactor
The FDA previously approved Signatera as a companion diagnostic for adjuvant atezolizumab in MIBC, a precedent referenced in the Japanese approval.
Importance 35.0 Sentiment 0.0
stock
Roche, as parent of F. Hoffmann-La Roche — Genentech, indirectly benefits from expanded companion diagnostic use of atezolizumab in Japan.
Importance 30.0 Sentiment 5.0
ngo
The NCCN published a Category 1 recommendation for MRD-guided adjuvant atezolizumab in bladder cancer, supporting adoption of Signatera-guided care.
Importance 20.0 Sentiment 0.0
exch
Nasdaq is the exchange where Natera shares trade, with the stock down 1.47 percent to $365.20 in pre-market trading following the announcement.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.